達(dá)格列凈聯(lián)合沙庫巴曲纈沙坦鈉片治療心腎綜合征的臨床研究

打開文本圖片集

Clinical Study of Dapagliflozin Combined with Sacubitril and Valsartan Sodium Tablets in the Treatment of Cardiorenal Syndrome/ZHOU Baoqin，KANG Wenling， JIANG Fang， ZHOU Qun， WANG Jian.//Medical Innovation of China，2025，22（18）：001-005

[Abstract]Objective： To explore the clinical studyof Dapagliflozin combined with Sacubitril and Valsartan Sodium Tablets inthe treatmentof cardiorenal syndrome （CRS）.Method：A totalof1O2 patients with CRSadmitted to from June 2O22 to June 2O24 were selected and divided into the control group （ n =49） and the combined group （n=53）by the random number table method.The control group was treated with Sacubitril and Valsartan Sodium Tablets， while the combined group was treated with Dapagliflozin combined with Sacubitril and Valsartan Sodium Tablets.The clinical eficacy，echocardiographic parameters[left ventricular ejection fraction （LVEF），leftventricularenddiastolicdiameter（LVEDD），interventricular septal thickness （IVST）]，andrelated indicators of cardiac and renal functions [N-terminal pro-brain natriuretic peptide（NT-proBNP），cardiac troponinI （cTnl），serum creatinine （Scr），and estimated glomerular filtrationrate （eGFR）]of the two groups were compared，and the occurrence of adverse reactions inboth groups was recorded.Result：The total efective rateof treatment inthe combined group was higher than that in the control group，the difference was statistically significant （ P <0.05）. After 6 months of treatment，the levels of LVEFand eGFR in both groups were higher than those before treatment，while thelevels ofLVEDD，IVST，NT-proBNP，cTnIandScrwerelowerthanthosebefore treatment; moreover，thelevels of LVEFand eGFR in the combined group were higherthan those in thecontrol group，the levelsof LVEDD， IVST， NT-proBNP，cTnIand Scr were all lower than those inthecontrol group，the diferences were statisticallysignificant （ P <0.05）.There was no statistically significant diference inthe incidence of adverse reactions between the two groups P>0.05 ）. Conclusion： Dapagliflozin combined with Sacubitril and Valsartan Sodium Tablets in the treatment of CRS can improve theclinical effct，effctively improvethe functions of the heart and kidneys，and has good drug safety.

[Key Words]Cardiorenal syndromeDapagliflozinSacubitril and Valsartan Sodium TabletsCardiac and renal protection

First-author'saddress：Nephrology，， 338ooo，China doi：10.3969/j.issn.1674-4985.2025.18.001

心腎綜合征（cardiorenalsyndrome，CRS）是臨床常見綜合征，多指心臟和腎功能不全相互加重，以端坐呼吸、水腫、腹水等為主要臨床表現(xiàn)，患者再住院率和死亡率均較高，故早期積極治療尤為重要。（剩余6008字）